Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone

详细信息    查看全文

• 作者：Lydie Tauchenová ; MD^a ; Barbora Kří ; žová ; MD^a ; Milo&scaron ; Kubá ; nek ; MD ; PhD^a ; ^mikb@ikem.cz ; Soňa Fraňková ; MD^b ; Vojtěch Melenovský ; MD ; PhD^a ; Jaroslav Tintěra ; MSc^c ; Dana Kautznerová ; MD^c ; Jana Malu&scaron ; ková ; MD^d ; Milan Jirsa ; MD ; PhD^d ; ^e ; Josef Kautzner ; MD ; PhD^a
• 刊名：Canadian Journal of Cardiology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：32
• 期：12
• 页码：1574.e1-1574.e3
• 全文大小：505 K
• 卷排序：32

文摘

There is scarce evidence regarding the use of iron chelators in patients with hereditary hemochromatosis who are intolerant of phlebotomy or erythrocytapheresis. A 52-year-old man with genetically confirmed HFE hemochromatosis presented with liver disease and heart failure with severe left ventricular systolic dysfunction. Because of anemia after initial treatment, we added intravenous deferoxamine followed by oral deferiprone to less frequent erythrocytapheresis, which normalized systolic function within 1 year. Repeated cardiac magnetic resonance imaging revealed improvement of the T2* relaxation time. This report illustrates the beneficial effect of iron chelators in individuals with HFE hemochromatosis and poor tolerance of erythrocytapheresis.